Laboratory point-of-care monitoring in the operating room

Current Opinion in Anaesthesiology

Volumn 23, Issue 6, 2010, Pages 741-748

  Rhee, Amanda J ^a   Kahn, Ronald A ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

arterial blood gas; coagulation; glucose; parathyroid hormone; platelet function; pointof care testing

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PARATHYROID HORMONE; PROTHROMBIN;

ANESTHESIA LEVEL; ANTICOAGULATION; ARTERIAL GAS; BLOOD CLOTTING TIME; GLYCEMIC CONTROL; HORMONE DETERMINATION; LABORATORY TEST; OPERATING ROOM; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REVIEW; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; TRANSCUTANEOUS OXYGEN MONITORING; VISCOELASTICITY;

CLINICAL LABORATORY INFORMATION SYSTEMS; HUMANS; LABORATORIES, HOSPITAL; MONITORING, INTRAOPERATIVE; OPERATING ROOMS; POINT-OF-CARE SYSTEMS;

EID: 78649475846     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32834015bd     Document Type: Review

References (74)

1. Gupta S, Bhattacharya A. Point-of-care testing in anaesthesiology and intensive care: An overview. Indian J Anaesth 2004; 48:278-286.
2. Gutierres SL, Welty TE. Point-of-care testing: An introduction. Ann Pharmacother 2004; 38:119-125.
3. Kumar RN, Arrowsmith JE. Point-of-care testing. Surgery 2006; 24:329-332.
4. Melanson S. What is new in point-of-care testing? J Near-Patient Test Technol 2009; 8:166-170.
5. Prisco D, Paniccia R. Point-of-care testing of hemostasis in cardiac surgery. Thromb J 2003; 1:1-10.
6. Van Cott EM. Point-of-care testing in coagulation. Clin Lab Med 2009; 29:543-553.
7. Fitch JC, Mirto GP, Geary KL, et al. Point-of-care and standard laboratory coagulation testing during cardiovascular surgery: Balancing reliability and timeliness. J Clin Monitor Comput 1999; 15:197-204.
8. Royston D, von Kier S. Reduced haemostatic factor transfusion using heparinase- modified thromboelastography during cardiopulmonary bypass. Br J Anaesth 2001; 86:575-578.
9. Shore-Lesserson L, Manspeizer HE, DPerio M, et al. Thromboelastographyguided transfusion algorithm reduces transfusion in complex cardiac surgery. Anesth Analg 1999; 88:312-319.
10. Enriquez LJ, Shore-Lesserson L. Point-of-care coagulation testing and transfusion algorithms. Br J Anaesth 2009; 103 (Suppl I):i14-i22.
11. Ganter MT, Hofer CK. Coagulation monitoring: Current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008; 106:1366-1375.
12. Chen A, Teruya J. Global hemostasis testing thromboelastography: Old technology, new applications. Clin Lab Med 2009; 29:391-407.
13. Artang R, Frandsen NJ, Nielsen JD. Application of basic and composite thrombelastography parameters in monitoring of the antithrombotic effect of the low molecular weight heparin dalteparin: An in vivo study. Thromb J 2009; 7:1-7. There are currently no POCT devices to monitor low molecular weight heparin. This study suggests that the R and TDR parameters on the TEG can be used to assess therapeutic anti-Xa levels.
14. Stahel PF, Moore EE, Schreier SL, et al. Transfusion strategies in postinjury coagulopathy. Curr Opin Anes 2009; 22:289-298.
15. Kashuk JL, Moore EE, Le T, et al. Noncitrated whole blood is optimal for evaluation of postinjury coagulopathy with point-of-care rapid thrombelastography. J Surg Res 2009; 156:133-138. A common practice for TEG usage is to mix blood with citrate to prevent premature clot formation before the sample can be processed. This study argues that the TEG with noncitrated blood is more accurate than one with citrated blood.
16. Kashuk JL, Moore EE, Sawyer M, et al. Postinjury coagulopathy management: Goal directed resuscitation via POC thrombelastography. Ann Surg 2010; 251:604-614.
17. Haas T, Fries D, Velik-Salchner C, et al. Fibrinogen in craniosynostosis surgery. Anesth Analg 2008; 106:725-731.
18. Straub A, Schiebold D, Wendel HP, et al. Using reagent-supported thromboelastometry (ROTEM) to monitor haemostatic changes in congenital heart surgery employing deep hypothermic circulatory arrest. Eur J Cardiothorac Surg 2008; 34:641-647.
19. Theusinger OM, Nü rnberg J, Asmis LM, et al. Rotation thromboelastometry (ROTEM1) stability and reproducibility over time. Eur J Cardiothorac Surg 2010; 37:677-683.
20. Dick A, Schwaiger M, Jambor C, et al. Thromboelastography/-metry and external quality control. Results of a pilot study. Hamostaseologie 2010; 30:91-95.
21. Peddinghaus ME, Tormey CA. Platelet-related bleeding: An update on diagnostic modalities and therapeutic options. Clin Lab Med 2009; 29:175-191.
22. Collet JP, Julot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 2009; 373:309-317.
23. Freedman JE, Hylek EM. Clopidogrel, genetics, and drug responsiveness. N Engl J Med 2009; 360:411-413.
24. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360:354-362.
25. Moerenhout CM, Claeys MJ, Haine S, et al. Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: Experience with the point-of-care platelet function assay-100C/ADP. Am Heart J 2010; 159:434-438. There has been a recent trend towards using POCT to evaluate therapeutic effectiveness of anticoagulants. These series of studies may reduce the number of adverse coronary events by better ensuring the attainment of appropriate anticoagulation goals.
26. Schuhmann CG, Sohn HY, Nagel J, et al. Clinical management of clopidogrel inefficiency by point of care platelet function testing and individual adjustment of antiplatelet therapy: Initial experiences. Platelets 2009; 20:498-504. There has been a recent trend towards using POCT to evaluate therapeutic effectiveness of anticoagulants. These series of studies may reduce the number of adverse coronary events by better ensuring the attainment of appropriate anticoagulation goals.
27. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53:849-856. There has been a recent trend towards using POCT to evaluate therapeutic effectiveness of anticoagulants. These series of studies may reduce the number of adverse coronary events by better ensuring the attainment of appropriate anticoagulation goals.
28. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360:363-375.
29. Pinto Slottow TL, Bonello L, Gavini R, et al. Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. Am J Cardiol 2009; 104:525-530. There has been a recent trend towards using POCT to evaluate therapeutic effectiveness of anticoagulants. These series of studies may reduce the number of adverse coronary events by better ensuring the attainment of appropriate anticoagulation goals.
30. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30:916-922.
31. Capodanno D, Angiolillo DJ. Platelet montoring for PCI. Which test is the one to choose? Hämostaseologie 2009; 29:376-380.
32. Ouwehand WH, Bloodomics and Wellcome Trust Case Control Consortia. Platelet genomics and the risk of atherothrombosis. J Thromb Haemost 2007; 5:188-195.
33. Boncoraglioa GB, Bodinib A, Brambillab C, et al. Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease. Clin Neurol Neurosurg 2009; 111:270-273. There has been a recent trend towards using POCT to evaluate therapeutic effectiveness of anticoagulants. These series of studies may reduce the number of adverse coronary events by better ensuring the attainment of appropriate anticoagulation goals.
34. Kidson-Gerber G, Weaver J, Gemmell R, et al. Serum thromboxane B2 compared to five other platelet function tests for the evaluation of aspirin effect in stable cardiovascular disease. Heart Lung Circ 2010; 19:234-242.
35. Bergmann L. Uneventful removal of an epidural catheter guided by impedance aggregometry in a patient with recent coronary stenting and treated with clopidogrel and acetylsalicylic acid. Reg Anesth Pain Med 2007; 32:354-357.
36. Siller-Matula, Christ G, Lang IM, et al. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost 2009; 8:351-359.
37. Can MM. The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: Comparison of the PFA-100, multiplate electrical impedance aggregometry and VerifyNow assays. Thromb Res 2010; 125:e132-e137.
38. Rahe-Meyer N, Winterhalter M, Boden A, et al. Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry. ACTA Anaesthesiol Scand 2009; 53:168-175.
39. Bertrand OF, Rodés-Cabau J, Rinfret S, et al. Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy. J Cardiol 2009; 104:1235-1240.
40. Kendall J, Reeves B, Clancy M. Point of care testing: Randomised controlled trial of clinical outcome. Br J Anaesth 1998; 316:1052-1057.
41. Peterson JR, Vonmarensdorf HM, Weiss HL, Elghetany MT. Use of error grid analysis to evaluate acceptability of a point of care prothrombin time meter. Clin Chim Acta 2010; 411:131-134.
42. Greenway A, Ignjatovic V, Summerhayes R, et al. Point-of-care monitoring of oral anticoagulation therapy in children. Comparison of the CoaguChek XS system with venous INR and venous INR using an International Reference Thromboplastin preparation (rTF/95). Thromb Haemost 2009; 102:159-165.
43. Urwyler N, Trelle S, Theiler L, et al. Does point of care prothrombin time measurement reduce the transfusion of fresh frozen plasma in patients undergoing major surgery? The POC-OP randomized-controlled trial. Thromb Haemost 2009; 10:1-9. An important application of POCT is to reduce unnecessary transfusion. This study suggests that the use of POCT decreases unnecessary fresh frozen plasma transfusion.
44. Hoel RW, Albright RC, Beyer LK, et al. Correlation of point-of-care international normalized ratio to laboratory international normalized ratio in hemodialysis patients taking warfarin. Clin J Am Soc Nephrol 2009; 4:99-104.
45. Tripodi A, Chantarangkul V, Primignani M, et al. Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement of INRliver for the calculation of the MELD score. J Hepatol 2009; 51:288-295. This study showed the POCT can be used to determine MELD score for liver transplant patients in an easier, standardized way compared to the current WHO standard of thromboplastin measurement.
46. Douglas AD, Jefferis J, Sharma R, et al. Evaluation of point-of-care activated partial thromboplastin time testing by comparison to laboratory-based assay for control of intravenous heparin. Angiology 2009; 60:358-361.
47. Urwyler N, Staub LP, Beran D, et al. Is perioperative point-of-care prothombin time testing accurate compared to the standard laboratory test? Thromb Haemost 2009; 102:779-786.
48. Van den Berghe G, Wilmer A, Milants I, et al. Intensive insulin therapy in mixed medical/surgical intensive care units: Benefit versus harm. Diabetes 2006; 55:3151-3159.
49. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283-1297. This study argued that intensive insulin therapy, a widely accepted glucose management strategy, was harmful to patients. It has shifted the practice of glycemic control by many to a more conservative approach.
50. Shearer A, Boehmer M, Closs M, et al. Comparison of glucose point-of-care values with laboratory values in critically ill patients. Am J Crit Care 2009; 18:224-230. This study suggests that POCT and laboratory glucose testing differ to the extent that it may alter therapeutic plans.
51. Alter D, Deines G. Tight glycemic control and point-of-care testing. Clin Lab Med 2009; 29:511-522.
52. Greene AB, Butler RS,McIntyre S, et al. National trends in parathyroid surgery from 1998 to 2008: A decade of change. Am Coll Surg 2009; 209:332-343.
53. Grant CS, Thompson G, Farley D, van Heerden J. Primary hyperparathyroidism surgical management since the introduction of minimally invasive parathyroidectomy: Mayo Clinic experience. Arch Surg 2005; 140:472-478.
54. Irvin GL, Carneiro DM, Solorzano CC. Progress in the operative management of sporadic primary hyperparathyroidism over 34 years. Ann Surg 2004; 239:704-708.
55. Lew JI, Solorzano CC. Surgical management of primary hyperparathyroidism: State of the art. Surg Clin North Am 2009; 89:1205-1225.
56. Udelsman R. Six hundred fifty six consecutive expoloration for primary hyperparathyroidism. Ann Surg 2002; 235:665-672.
57. Westerdahl J, Lindblom P, Bergenfelz A. Measurement of intraoperative parathyroid hormone predicts long-term operative success. Arch Surg 2002; 137:186-190.
58. Pitt SC, Sippel RS, Chen H. Secondary and tertiary hyperparathyroidism, state of the art surgical management. Surg Clin North Am 2009; 89:1227-1239.
59. Sokoll LJ, Wians FH, Remaley AT. Rapid intraoperative immunoassay of parathyroid hormone and other hormones: A new paradigm for point-of-care testing. Clin Chem 2004; 50:1126-1135.
60. Chan YW, Woods JJ, Nunes J, et al. Development of a rapid intraoperative ACTH assay on the Nichols Advantage analyzer. Clin Chem 2000; 46 (Suppl 6):A120-A121.
61. Czirjak S, Bezzegh A, Gál A, Rácz K. Intra-and postoperative plasma ACTH concentrations in patients with Cushing's disease cured by transsphenoidal pituitary surgery. Acta Neurochir (Wein) 2002; 144:971-977. (Pubitemid 35232026)
62. Graham KE, Samuels MH, Raff H, et al. Intraoperative adrenocorticotropic levels during transsphenoidal surgery for Cushing's disease do not predict cure. J Clin Endocrinol Metab 1997; 82:1776-1779.
63. Raff H, Shaker JL, Seifert PE, et al. Intraoperative measurement of adrenocorticotropin (ACTH) during removal of ACTH-secreting bronchial carcinoid tumors. J Clin Endocrinol Metab 1995; 80:1036-1039.
64. Campbell S, Howanitz PJ. Resident training in point-of-care testing. Clin Lab Med 2007; 27:397-410.
65. Ehrmeyer SS, Laessig RH. Regulatory compliance for point-of-care testing: 2009 United States perspective. Clin Lab Med 2009; 29:463-478.
66. Ganter MT, Schneider U, Heinzelmann M, et al. How often should we perform arterial blood gas analysis during thoracoscopic surgery? J Clin Anesth 2007; 19:569-575.
67. Gregory K, Lewandrowski K. Management of a point-of-care testing program. Clin Lab Med 2009; 29:433-448.
68. Kim JK, Lewandrowski K. Point-of-care testing informatics. Clin Lab Med 2009; 29:449-461.
69. Lee-Lewandrowski E, Lewandrowski K. Perspectives on cost and outcomes for point-of-care testing. Clin Lab Med 2009; 29:479-489.
70. Lewandrowski K. Point-of-care testing: An overview and a look to the future (circa 2009, United States). Clin Lab Med 2009; 29:421-432.
71. Maddox JM, Bogo PH, McGregor E, et al. Quality assurance for point-of-care testing of oral anticoagulation: A large-scale evaluation of the Hemochron Junior Signature Microcoagulation System. Int J Lab Hematol 2009; 31:142-150.
72. O'Connell DA, Harris SH. Central laboratory versus point-of-care testing in intraoperative monitoring of parathyroid hormone levels: Cost comparison. J Otolaryngol Head Neck Surg 2008; 37:91-97.
73. Wax DB, Reich DL. Changes in utilization of intraoperative laboratory testing associated with introduction of point-of-care testing devices in an academic department. Anesth Analg 2007; 105:1711-1713.
74. Westbrook AJ, Olsen J, Bailey M, et al. Protocol based on thromboelastograph out-performs physician preference using laboratory coagulation tests to guide blood replacement during and after cardiac surgery: A pilot study. Heart Lung Circ 2009; 18:277-288.